 Your new post is loading...
 Your new post is loading...
|
Scooped by
Judy Curtis / SIPR
October 12, 2020 1:46 PM
|
"Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to the CPhI Annual report for 2020"
|
Scooped by
Judy Curtis / SIPR
July 2, 2020 4:19 PM
|
Manufacturers are adapting with virtual work, remote monitoring, and re-evaluation of facility design and operation to ensure worker safety.
|
Scooped by
Judy Curtis / SIPR
June 12, 2020 9:54 AM
|
Much has been made of the potential of continuous platforms to supplant traditional pharmaceutical batch manufacturing and drive down API production costs. But how suitable is the technology to the precise requirements of complex pharma processing?
|
Scooped by
Judy Curtis / SIPR
April 24, 2020 9:51 AM
|
Chief Editor Louis Garguilo asked Outsourced Pharma Advisory Board member and COO/CSO of Pharmatech Associates, Bikash Chatterjee, to talk about building in quality to manufacture ventilators.
|
Scooped by
Judy Curtis / SIPR
April 3, 2020 9:46 AM
|
Driven by digitalisation, Pharma 4.0 is envisioned as the next step in the evolution of pharmaceutical manufacturing. It reflects a shift to improving business performance through data analyses and structured decision-making across the entire pharmaceutical manufacturing value chain.
|
Scooped by
Judy Curtis / SIPR
March 4, 2020 4:47 PM
|
"As we face our latest pandemic threat, the need to have a well-defined and tested business continuity management plan in place cannot be overemphasized." - Bikash Chatterjee, Pharmatech Associates
|
Scooped by
Judy Curtis / SIPR
January 6, 2020 9:45 PM
|
"Drug sponsors looking to enter the pharmaceutical markets of China, Japan, and India are faced with regulatory requirements specific to each market, from planning to clinical studies"
|
Scooped by
Judy Curtis / SIPR
October 25, 2019 10:58 AM
|
You Brexit, You Buy It – Europe and the New Regulatory – Part 2 By Lynn Hansen, Director of Clinical and Regulatory Affairs, Pharmatech Associates
|
Scooped by
Judy Curtis / SIPR
October 21, 2019 7:53 PM
|
Amsterdam, 21 October 2019: CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th-7th November 2019) – has released the first part of its eponymous 2019 Annual Report. Experts Bikash Chatterjee, President and Chief Science Officer at Pharmtech Associates and Girish Malhotra, President of EPCOT International, discuss how manufacturing could be revolutionised by new technologies, but warn, that regulators must change to prevent hindering future innovation.
|
Scooped by
Judy Curtis / SIPR
October 4, 2019 12:23 PM
|
The new EU draft guidance, Guideline on the Quality Requirements for Drug-Device Combinations, diverges from the U.S. draft guidance. Part 2 of a two-part series examines the EU guidelines.
|
Scooped by
Judy Curtis / SIPR
September 30, 2019 3:54 PM
|
One of the inevitable consequences of political change is disruption to the global economic engine. Disruption can result from political instability, regulation, or even innovation. Now, from the portent of the coming Brexit storm, to the enactment of major provisions of the Drug Quality Security Act (DSCA), to the promise of blockchain and artificial intelligence (AI), the requirements for modern supply chain management are in evolution, as are the efforts underway to safeguard supply chain integrity.
|
Scooped by
Judy Curtis / SIPR
July 1, 2019 4:07 PM
|
The Premarket Notification (510(k)) pathway for medical device approval presents challenges for device manufacturers, FDA reviewers, and patients.
|
Scooped by
Judy Curtis / SIPR
May 21, 2019 12:42 PM
|
Regulatory, cultural, and technical differences between drug and device development can pose challenges.
|
|
Scooped by
Judy Curtis / SIPR
August 11, 2020 9:57 AM
|
This year saw a significant change in the process for submitting drug master files (DMFs) for biologic products: as of March 23, biologic-related DMFs are now administered by the FDA’s Center for Biologics Evaluation and Research (CBER). This transition of responsibilities presents a number of challenges for sponsors accustomed to working under the Center for Drug Evaluation and Research ( CDER).
|
Scooped by
Judy Curtis / SIPR
June 24, 2020 4:32 PM
|
Controlled Release Roundtable, pp 58-65
|
Scooped by
Judy Curtis / SIPR
May 19, 2020 10:29 AM
|
The FDA is authorized to grant Emergency Use Authorizations for any medical countermeasure that facilitates the diagnosis, prevention, or treatment of SARS-CoV-2.
|
Scooped by
Judy Curtis / SIPR
April 22, 2020 10:56 AM
|
Reducing risk while while maintaining process velocity are key to defeating this virus
|
Scooped by
Judy Curtis / SIPR
April 3, 2020 8:43 AM
|
It is critical that organizations looking to engage an external contract service provider be aware of new regulations to align their program
|
Scooped by
Judy Curtis / SIPR
February 3, 2020 10:03 PM
|
The FDA issued draft guidance on the qualification process for drug development tools (DDTs) in December 2019
|
Scooped by
Judy Curtis / SIPR
November 1, 2019 12:35 PM
|
The FDA's new pharmaceutical quality assessment system is intended to capture and manage information about inherent risk and control approaches for product design, manufacturing, and facilities
|
Scooped by
Judy Curtis / SIPR
October 24, 2019 4:37 PM
|
You Brexit, You Buy It – Europe and the New Regulatory – Part 1 of 2, By Lynn Hansen, Director of Clinical and Regulatory Affairs, Pharmatech Associates. With Brexit looming, questions and concerns hover like a grey cloud over the UK pharmaceutical industry. Industry insiders and colleagues in London found that the confusion surrounding what comes next was offset by a constant and wearying news update on Brexit…
|
Scooped by
Judy Curtis / SIPR
October 15, 2019 11:41 AM
|
The goal of Pharma 4.0 is to create the intelligence needed for engineers and operators to make smarter decisions that increase operational efficiencies, improve yields, and drive business performance.
|
Scooped by
Judy Curtis / SIPR
October 1, 2019 12:17 PM
|
Pharma 4.0 & IoT: Applications across the Drug Development Life Cycle and Supply Chain Pharma 4.0 applies Industry 4.0 concepts to the pharmaceutical setting. Within modular structured smart factories, cyber-physical systems monitor physical processes, create a virtual copy of the physical world, and help make decentralized decisions.
|
Scooped by
Judy Curtis / SIPR
September 20, 2019 8:10 PM
|
Designing Combination products for compliance: Caitlin Bancroft of Pharmatech analyses the new U.S. draft guidance (part 1) and the EU draft guidance in a two-part article in Pharmaceutical Online.
|
Scooped by
Judy Curtis / SIPR
May 31, 2019 9:46 AM
|
If we are to jump into cGMP, where is the line of converting from 361 to 351 Regulations and Practices for a manufacturing facility drawn?
|
Bikash Chatterjee, CEO of Pharmatech Associates, said the concept of patient centricity has gone beyond being a buzzword to being a core value and that telemedicine will have a long-lasting impact.
Chatterjee also foresees the industry will see voice collection of data in the home begin to be incorporated into both home and health settings.